To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Insulin glulisine
Insulin glulisine is a rapid-acting insulin analogue that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid. Chemically, it is 3B-lysine-29B-glutamic acid-human insulin, has the empirical formula C258H384N64O78S6 and a molecular weight of 5823. It was developed by Sanofi-Aventis and sold under the trade name Apidra®. When injected subcutaneously, it appears in the blood earlier and at higher concentrations that human insulin. When used as a meal time insulin, the dose should be given within 15 minutes before a meal or within 20 minutes after starting a meal.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Insulin_glulisine". A list of authors is available in Wikipedia. |
- A Brief Summary of Disinfectants & Antiseptics
- Scientists accelerate spectroscopic analysis - "This innovation expands the application of compressed sensing to real-time spectroscopic measurement"
- Wacker opens a new plant for functional silicone fluids in India
- AkzoNobel cooperates with Itaconix - Agreement on development of bio-based polymers
- Van Berkel earns Biemann Medal for contributions to mass spec field